Charles Swanton, MBPhD, FRCP, FMedSci, FRS, FAACR

Charles Swanton, MBPhD, FRCP, FMedSci, FRS, FAACR

Royal Society Napier Professor
The Francis Crick Institute and UCL Cancer Institute
Cancer Evolution and Genome Instability Lab
The Francis Crick Institute
London, England

Dr. Swanton completed his MBPhD training in 1999 at the Imperial Cancer Research Fund Laboratories and Cancer Research UK clinician scientist/medical oncology training in 2008. He is a senior group leader of the Cancer Evolution and Genome Instability Laboratory at the Francis Crick Institute, and he combines his research with his clinical duties at UCLH as a thoracic oncologist, focused on how tumors evolve over space and time. His research branched evolutionary histories of solid tumors, processes that drive cancer cell-to-cell variation in the form of new cancer mutations or chromosomal instabilities, and the impact of such cancer diversity on effective immune surveillance and clinical outcome. Swanton is chief investigator of TRACERx, a lung cancer evolutionary study and the national PEACE autopsy program.

Swanton was made Fellow of the Royal College of Physicians in April 2011, appointed Fellow of the Academy of Medical Sciences in 2015, awarded the Napier Professor in Cancer by the Royal Society in 2016, appointed Cancer Research UK’s Chief Clinician in 2017, elected Fellow of the Royal Society in 2018, and Fellow of the Academy of the American Association for Cancer Research in 2020. He is an editorial board member of Cell, PLOS Medicine, Cancer Discovery, and Annals of Oncology and an advisory board member for Nature Reviews Clinical Oncology and Cancer Cell. In 2016, he co-founded Achilles Therapeutics, a UCL/CRUK/Francis Crick Institute spinout company that assesses the efficacy of T cells targeting clonal neoantigens.

Swanton has been awarded several prizes, including the Stand up to Cancer Translational Cancer Research Prize (2015), GlaxoSmithkline Biochemical Society Prize (2016), San Salvatore Prize for Cancer Research (2017) and the Ellison-Cliffe Medal, Royal Society of Medicine (2017), recipient of the Gordon Hamilton Fairley Medal (2018), Massachusetts General Hospital, Jonathan Kraft Prize for Excellence in Cancer Research (May 2018), the ESMO Award for Translational Cancer Research (2019), Addario Lung Cancer Foundation Award and Lectureship, International Lung Cancer Congress (July 2020) and the Weizmann Institute Sergio Lambroso Award in Cancer Research (2021).